Targeting AMPK for cancer prevention and treatment

Oncotarget

Volumn 6, Issue 10, 2015, Pages 7365-7378

  Li, Weidong ^a,c   Saud, Shakir M ^b,c   Young, Matthew R ^c   Chen, Guohong ^a   Hua, Baojin ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

AMP activated kinase; Cancer; Prevention; Treatment

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ANTROQUINONOL; BERBERINE; CRYPTOTANSHINONE; CURCUMIN; CYCLOOXYGENASE 2; DEMETHOXYCURCUMIN; EPIGALLOCATECHIN GALLATE; GINSENOSIDE; GINSENOSIDE 20 O BETA DEXTRO GLUCOPYRANOSYL 20 PROTOPANAXADIOL; HONOKIOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAGNOLOL; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; NORDIHYDROGUAIARETIC ACID; PHOSPHORIBOSYLAMINOIMIDAZOLECARBOXAMIDE FORMYLTRANSFERASE; PLANT MEDICINAL PRODUCT; PROTEIN KINASE B; PROTEIN KINASE LKB1; PROTEIN P53; QUERCETIN; RESVERATROL; TANSHINONE IIA; UNCLASSIFIED DRUG; WIDDROL; WOGONIN;

APOPTOSIS; BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; CANCER PREVENTION; CANCER THERAPY; CARCINOGENICITY; CHINESE MEDICINE; COLON CANCER; COLORECTAL CANCER; DRUG EFFICACY; ENZYME SYNTHESIS; GENE MUTATION; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; INFLAMMATION; LEUKEMIA; LIVER CELL CARCINOMA; MELANOMA; METABOLIC SYNDROME X; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; ENZYMOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84928382161     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3629     Document Type: Review

References (145)

1. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nature reviews Molecular cell biology. 2007; 8:774-785.
2. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA and Cantley LC. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101:3329-3335.
3. Chen Z, Shen X, Shen F, Zhong W, Wu H, Liu S and Lai J. TAK1 activates AMPK-dependent cell death pathway in hydrogen peroxide-treated cardiomyocytes, inhibited by heat shock protein-70. Molecular and cellular biochemistry. 2013; 377:35-44.
4. Jeon SM, Chandel NS and Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature. 2012; 485:661-665.
5. Yao F, Ji GY and Zhang L. [AMPK: a novel target controlling inflammation]. Sheng li xue bao: [Acta physiologica Sinica]. 2012; 64:341-345.
6. Yue W, Yang CS, DiPaola RS and Tan XL. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. Cancer prevention research. 2014; 7:388-397.
7. Hwang JT, Kwak DW, Lin SK, Kim HM, Kim YM and Park OJ. Resveratrol induces apoptosis in chemoresistant cancer cells via modulation of AMPK signaling pathway. Annals of the New York Academy of Sciences. 2007; 1095:441-448.
8. Lin JN, Lin VC, Rau KM, Shieh PC, Kuo DH, Shieh JC, Chen WJ, Tsai SC and Way TD. Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation. Journal of agricultural and food chemistry. 2010; 58:1584-1592.
9. Rashid A, Liu C, Sanli T, Tsiani E, Singh G, Bristow RG, Dayes I, Lukka H, Wright J and Tsakiridis T. Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. Radiation oncology. 2011; 6:144.
10. Shen Y, Croft KD, Hodgson JM, Kyle R, Lee IL, Wang Y, Stocker R and Ward NC. Quercetin and its metabolites improve vessel function by inducing eNOS activity via phosphorylation of AMPK. Biochemical pharmacology. 2012; 84:1036-1044.
11. Kim HS, Kim MJ, Kim EJ, Yang Y, Lee MS and Lim JS. Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. Biochemical pharmacology. 2012; 83:385-394.
12. Li Y, Wang P, Zhuang Y, Lin H, Li Y, Liu L, Meng Q, Cui T, Liu J and Li Z. Activation of AMPK by berberine promotes adiponectin multimerization in 3T3-L1 adipocytes. FEBS letters. 2011; 585:1735-1740.
13. Jeong HW, Hsu KC, Lee JW, Ham M, Huh JY, Shin HJ, Kim WS and Kim JB. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. American journal of physiology Endocrinology and metabolism. 2009; 296:E955-964.
14. Wullschleger S, Loewith R and Hall MN. TOR signaling in growth and metabolism. Cell. 2006; 124:471-484.
15. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ and Thompson CB. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Molecular cell. 2005; 18:283-293.
16. Leclerc I, Lenzner C, Gourdon L, Vaulont S, Kahn A and Viollet B. Hepatocyte nuclear factor-4alpha involved in type 1 maturity-onset diabetes of the young is a novel target of AMP-activated protein kinase. Diabetes. 2001; 50:1515-1521.
17. Kawaguchi T, Osatomi K, Yamashita H, Kabashima T and Uyeda K. Mechanism for fatty acid "sparing" effect on glucose-induced transcription: regulation of carbohydrateresponsive element-binding protein by AMP-activated protein kinase. The Journal of biological chemistry. 2002; 277:3829-3835.
18. Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M, Kondo S, Dumont DJ, Gutterman JU, Walker CL, Slingerland JM and Mills GB. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nature cell biology. 2007; 9:218-224.
19. O'Neill LA and Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature. 2013; 493:346-355.
20. Habegger KM, Hoffman NJ, Ridenour CM, Brozinick JT and Elmendorf JS. AMPK enhances insulin-stimulated GLUT4 regulation via lowering membrane cholesterol. Endocrinology. 2012; 153:2130-2141.
21. Rodrigue-Way A, Keil S, Caron V, Bilodeau S, Levy E, Mitchell GA and Tremblay A. Scavenger Receptor CD36 Mediates Inhibition of Cholesterol Synthesis via Activation of the LKB1-AMPK Pathway and Insig1/Insig2 Expression in Hepatocytes. Canadian journal of diabetes. 2013; 37 Suppl 4:S65.
22. Mihaylova MM and Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nature cell biology. 2011; 13:1016-1023.
23. Viollet B, Horman S, Leclerc J, Lantier L, Foretz M, Billaud M, Giri S and Andreelli F. AMPK inhibition in health and disease. Critical reviews in biochemistry and molecular biology. 2010; 45:276-295.
24. Hardie DG, Ross FA and Hawley SA. AMP-activated protein kinase: a target for drugs both ancient and modern. Chemistry & biology. 2012; 19:1222-1236.
25. Li YY, Yu LF, Zhang LN, Qiu BY, Su MB, Wu F, Chen DK, Pang T, Gu M, Zhang W, Ma WP, Jiang HW, Li JY, Nan FJ and Li J. Novel small-molecule AMPK activator orally exerts beneficial effects on diabetic db/db mice. Toxicology and applied pharmacology. 2013; 273:325-334.
26. Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, Wierzbicki M, Verbeuren TJ and Cohen RA. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes. 2006; 55:2180-2191.
27. Li J, Qi D, Cheng H, Hu X, Miller EJ, Wu X, Russell KS, Mikush N, Zhang J, Xiao L, Sherwin RS and Young LH. Urocortin 2 autocrine/paracrine and pharmacologic effects to activate AMP-activated protein kinase in the heart. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110:16133-16138.
28. Steinberg GR and Kemp BE. AMPK in Health and Disease. Physiological reviews. 2009; 89:1025-1078.
29. Pavlides S, Tsirigos A, Migneco G, Whitaker-Menezes D, Chiavarina B, Flomenberg N, Frank PG, Casimiro MC, Wang C, Pestell RG, Martinez-Outschoorn UE, Howell A, Sotgia F and Lisanti MP. The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell cycle. 2010; 9:3485-3505.
30. Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B, Pavlides S, Wang C, Whitaker-Menezes D, Daumer KM, Lin Z, Witkiewicz AK, Flomenberg N, Howell A, Pestell RG, Knudsen ES, Sotgia F and Lisanti MP. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell cycle. 2010; 9:3256-3276.
31. Kang J, Shakya A and Tantin D. Stem cells, stress, metabolism and cancer: a drama in two Octs. Trends in biochemical sciences. 2009; 34:491-499.
32. William WN, Kim JS, Liu DD, Solis L, Behrens C, Lee JJ, Lippman SM, Kim ES, Hong WK, Wistuba, II and Lee HY. The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2012; 23:78-85.
33. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008; 455:1069-1075.
34. Memmott RM, Gills JJ, Hollingshead M, Powers MC, Chen Z, Kemp B, Kozikowski A and Dennis PA. Phosphatidylinositol ether lipid analogues induce AMPactivated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells. Cancer research. 2008; 68:580-588.
35. Carretero J, Medina PP, Blanco R, Smit L, Tang M, Roncador G, Maestre L, Conde E, Lopez-Rios F, Clevers HC and Sanchez-Cespedes M. Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene. 2007; 26:1616-1625.
36. Matsumoto S, Iwakawa R, Takahashi K, Kohno T, Nakanishi Y, Matsuno Y, Suzuki K, Nakamoto M, Shimizu E, Minna JD and Yokota J. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene. 2007; 26:5911-5918.
37. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010. CA: a cancer journal for clinicians. 2010; 60:277-300.
38. Baba Y, Nosho K, Shima K, Meyerhardt JA, Chan AT, Engelman JA, Cantley LC, Loda M, Giovannucci E, Fuchs CS and Ogino S. Prognostic significance of AMPactivated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. British journal of cancer. 2010; 103:1025-1033.
39. Petti C, Vegetti C, Molla A, Bersani I, Cleris L, Mustard KJ, Formelli F, Hardie GD, Sensi M and Anichini A. AMPK activators inhibit the proliferation of human melanomas bearing the activated MAPK pathway. Melanoma research. 2012; 22:341-350.
40. Zhao Y, Tan Y, Xi S, Li Y, Li C, Cui J, Yan X, Li X, Wang G, Li W and Cai L. A novel mechanism by which SDF-1beta protects cardiac cells from palmitate-induced endoplasmic reticulum stress and apoptosis via CXCR7 and AMPK/p38 MAPK-mediated interleukin-6 generation. Diabetes. 2013; 62:2545-2558.
41. Bosch FX, Ribes J, Diaz M and Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004; 127(5 Suppl 1):S5-S16.
42. Smith RJ. Nutrition and metabolism in hepatocellular carcinoma. Hepatobiliary surgery and nutrition. 2013; 2:89-96.
43. Huang YH, Chen ZK, Huang KT, Li P, He B, Guo X, Zhong JQ, Zhang QY, Shi HQ, Song QT, Yu ZP and Shan YF. Decreased expression of LKB1 correlates with poor prognosis in hepatocellular carcinoma patients undergoing hepatectomy. Asian Pacific journal of cancer prevention: APJCP. 2013; 14:1985-1988.
44. Zheng L, Yang W, Wu F, Wang C, Yu L, Tang L, Qiu B, Li Y, Guo L, Wu M, Feng G, Zou D and Wang H. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19:5372-5380.
45. Cheng J, Huang T, Li Y, Guo Y, Zhu Y, Wang Q, Tan X, Chen W, Zhang Y, Cheng W, Yamamoto T, Jing X and Huang J. AMP-activated protein kinase suppresses the in vitro and in vivo proliferation of hepatocellular carcinoma. PloS one. 2014; 9:e93256.
46. Yi G, He Z, Zhou X, Xian L, Yuan T, Jia X, Hong J, He L and Liu J. Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway. International journal of oncology. 2013; 43:1503-1510.
47. Hu M, Huang H, Zhao R, Li P, Li M, Miao H, Chen N and Chen M. AZD8055 induces cell death associated with autophagy and activation of AMPK in hepatocellular carcinoma. Oncology reports. 2014; 31:649-656.
48. Kang S, Kim JE, Song NR, Jung SK, Lee MH, Park JS, Yeom MH, Bode AM, Dong Z and Lee KW. The ginsenoside 20-O-beta-D-glucopyranosyl-20(S)-protopanaxadiol induces autophagy and apoptosis in human melanoma via AMPK/JNK phosphorylation. PloS one. 2014; 9:e104305.
49. Cerezo M, Tichet M, Abbe P, Ohanna M, Lehraiki A, Rouaud F, Allegra M, Giacchero D, Bahadoran P, Bertolotto C, Tartare-Deckert S, Ballotti R and Rocchi S. Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. Molecular cancer therapeutics. 2013; 12:1605-1615.
50. Borgdorff V, Rix U, Winter GE, Gridling M, Muller AC, Breitwieser FP, Wagner C, Colinge J, Bennett KL, Superti-Furga G and Wagner SN. A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF. Oncogene. 2014; 33:2531-2539.
51. Ambrosini G, Musi E, Ho AL, de Stanchina E and Schwartz GK. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death. Molecular cancer therapeutics. 2013; 12:768-776.
52. Woodard J and Platanias LC. AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival. Biochemical and biophysical research communications. 2010; 398:135-139.
53. Taliaferro-Smith L, Nagalingam A, Zhong D, Zhou W, Saxena NK and Sharma D. LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene. 2009; 28:2621-2633.
54. Phoenix KN, Vumbaca F and Claffey KP. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast cancer research and treatment. 2009; 113:101-111.
55. Fox MM, Phoenix KN, Kopsiaftis SG and Claffey KP. AMP-Activated Protein Kinase alpha 2 Isoform Suppression in Primary Breast Cancer Alters AMPK Growth Control and Apoptotic Signaling. Genes & cancer. 2013; 4:3-14.
56. Kim HS, Kim MJ, Lim J, Yang Y, Lee MS and Lim JS. NDRG2 overexpression enhances glucose deprivationmediated apoptosis in breast cancer cells via inhibition of the LKB1-AMPK pathway. Genes & cancer. 2014; 5:175-185.
57. Chhipa RR, Wu Y and Ip C. AMPK-mediated autophagy is a survival mechanism in androgen-dependent prostate cancer cells subjected to androgen deprivation and hypoxia. Cellular signalling. 2011; 23:1466-1472.
58. Frigo DE, Howe MK, Wittmann BM, Brunner AM, Cushman I, Wang Q, Brown M, Means AR and McDonnell DP. CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgendependent migration of prostate cancer cells. Cancer research. 2011; 71:528-537.
59. Li C, Liu VW, Chiu PM, Yao KM, Ngan HY and Chan DW. Reduced expression of AMPK-beta1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer. Molecular cancer. 2014; 13:49.
60. Kandala PK and Srivastava SK. Regulation of macroautophagy in ovarian cancer cells in vitro and in vivo by controlling glucose regulatory protein 78 and AMPK. Oncotarget. 2012; 3:435-449.
61. Vakana E and Platanias LC. AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications. Oncotarget. 2011; 2:1322-1328.
62. Hadad SM, Baker L, Quinlan PR, Robertson KE, Bray SE, Thomson G, Kellock D, Jordan LB, Purdie CA, Hardie DG, Fleming S and Thompson AM. Histological evaluation of AMPK signalling in primary breast cancer. BMC cancer. 2009; 9:307.
63. Zong H, Yin B, Zhou H, Cai D, Ma B and Xiang Y. Inhibition of mTOR pathway attenuates migration and invasion of gallbladder cancer via EMT inhibition. Molecular biology reports. 2014.
64. Inoki K, Zhu T and Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003; 115:577-590.
65. Rubinsztein DC, Gestwicki JE, Murphy LO and Klionsky DJ. Potential therapeutic applications of autophagy. Nature reviews Drug discovery. 2007; 6:304-312.
66. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM and Gray NS. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. The Journal of biological chemistry. 2009; 284:8023-8032.
67. Kandadi MR, Hu N and Ren J. ULK1 plays a critical role in AMPK-mediated myocardial autophagy and contractile dysfunction following acute alcohol challenge. Current pharmaceutical design. 2013; 19:4874-4887.
68. Mack HI, Zheng B, Asara JM and Thomas SM. AMPKdependent phosphorylation of ULK1 regulates ATG9 localization. Autophagy. 2012; 8:1197-1214.
69. Mao K and Klionsky DJ. AMPK activates autophagy by phosphorylating ULK1. Circulation research. 2011; 108:787-788.
70. Tripathi DN, Chowdhury R, Trudel LJ, Tee AR, Slack RS, Walker CL and Wogan GN. Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated suppression of mTORC1. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110:E2950-2957.
71. Prescott SM and Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochimica et biophysica acta. 2000; 1470:M69-78.
72. Castellone MD, Teramoto H, Williams BO, Druey KM and Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science. 2005; 310:1504-1510.
73. Williams CS, Mann M and DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999; 18:7908-7916.
74. Williams C, Shattuck-Brandt RL and DuBois RN. The role of COX-2 in intestinal cancer. Annals of the New York Academy of Sciences. 1999; 889:72-83.
75. Hwang JT, Kim YM, Surh YJ, Baik HW, Lee SK, Ha J and Park OJ. Selenium regulates cyclooxygenase-2 and extracellular signal-regulated kinase signaling pathways by activating AMP-activated protein kinase in colon cancer cells. Cancer research. 2006; 66:10057-10063.
76. Lee YK, Park SY, Kim YM and Park OJ. Regulatory effect of the AMPK-COX-2 signaling pathway in curcumininduced apoptosis in HT-29 colon cancer cells. Annals of the New York Academy of Sciences. 2009; 1171:489-494.
77. Lee JY, Choi AY, Oh YT, Choe W, Yeo EJ, Ha J and Kang I. AMP-activated protein kinase mediates T cell activationinduced expression of FasL and COX-2 via protein kinase C theta-dependent pathway in human Jurkat T leukemia cells. Cellular signalling. 2012; 24:1195-1207.
78. Saini MK, Sharma P, Kaur J and Sanyal SN. The cyclooxygenase-2 inhibitor etoricoxib is a potent chemopreventive agent of colon carcinogenesis in the rat model. Journal of environmental pathology, toxicology and oncology: official organ of the International Society for Environmental Toxicology and Cancer. 2009; 28:39-46.
79. Furukawa F, Nishikawa A, Lee IS, Kanki K, Umemura T, Okazaki K, Kawamori T, Wakabayashi K and Hirose M. A cyclooxygenase-2 inhibitor, nimesulide, inhibits postinitiation phase of N-nitrosobis(2-oxopropyl)amineinduced pancreatic carcinogenesis in hamsters. International journal of cancer Journal international du cancer. 2003; 104:269-273.
80. Vogelstein B, Lane D and Levine AJ. Surfing the p53 network. Nature. 2000; 408:307-310.
81. Vousden KH and Prives C. Blinded by the Light: The Growing Complexity of p53. Cell. 2009; 137:413-431.
82. Lee EJ, Kim TJ, Kim DS, Choi CH, Lee JW, Lee JH, Bae DS and Kim BG. p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review. Gynecologic oncology. 2010; 116:533-538.
83. Okoshi R, Ozaki T, Yamamoto H, Ando K, Koida N, Ono S, Koda T, Kamijo T, Nakagawara A and Kizaki H. Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. The Journal of biological chemistry. 2008; 283:3979-3987.
84. Phoenix KN, Devarakonda CV, Fox MM, Stevens LE and Claffey KP. AMPKalpha2 Suppresses Murine Embryonic Fibroblast Transformation and Tumorigenesis. Genes & cancer. 2012; 3:51-62.
85. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B and Thompson CB. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer research. 2007; 67:6745-6752.
86. Zakikhani M, Dowling R, Fantus IG, Sonenberg N and Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer research. 2006; 66:10269-10273.
87. Hardie DG and Pan DA. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochemical Society transactions. 2002; 30:1064-1070.
88. Yi X, Cao S, Chang B, Zhao D, Gao H, Wan Y, Shi J, Wei W and Guan Y. Effects of acute exercise and chronic exercise on the liver leptin-AMPK-ACC signaling pathway in rats with type 2 diabetes. Journal of diabetes research. 2013; 2013:946432.
89. Janovska A, Hatzinikolas G, Staikopoulos V, McInerney J, Mano M and Wittert GA. AMPK and ACC phosphorylation: effect of leptin, muscle fibre type and obesity. Molecular and cellular endocrinology. 2008; 284:1-10.
90. Moore F and Brophy PJ. Regulation of acetyl-CoA carboxylase (ACC) by ATP depletion in developing oligodendrocytes mimics the action of AMP-activated protein kinase (AMPK). Biochemical Society transactions. 1994; 22:416S.
91. Feng Z, Hu W, de Stanchina E, Teresky AK, Jin S, Lowe S and Levine AJ. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer research. 2007; 67:3043-3053.
92. Beckers A, Organe S, Timmermans L, Scheys K, Peeters A, Brusselmans K, Verhoeven G and Swinnen JV. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer research. 2007; 67:8180-8187.
93. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J and Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer research. 2006; 66:1500-1508.
94. Leclerc GM, Leclerc GJ, Fu G and Barredo JC. AMPKinduced activation of Akt by AICAR is mediated by IGF-1R dependent and independent mechanisms in acute lymphoblastic leukemia. Journal of molecular signaling. 2010; 5:15.
95. Tao R, Gong J, Luo X, Zang M, Guo W, Wen R and Luo Z. AMPK exerts dual regulatory effects on the PI3K pathway. Journal of molecular signaling. 2010; 5:1.
96. Rattan R, Giri S, Singh AK and Singh I. 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. The Journal of biological chemistry. 2005; 280:39582-39593.
97. Choudhury Y, Yang Z, Ahmad I, Nixon C, Salt IP and Leung HY. AMP-activated protein kinase (AMPK) as a potential therapeutic target independent of PI3K/Akt signaling in prostate cancer. Oncoscience. 2014; 1:446-456.
98. Dandapani M and Hardie DG. AMPK: opposing the metabolic changes in both tumour cells and inflammatory cells? Biochemical Society transactions. 2013; 41:687-693.
99. Carroll KC, Viollet B and Suttles J. AMPKalpha1 deficiency amplifies proinflammatory myeloid APC activity and CD40 signaling. Journal of leukocyte biology. 2013; 94:1113-1121.
100. Hoogendijk AJ, Pinhancos SS, van der Poll T and Wieland CW. AMP-activated protein kinase activation by 5-aminoimidazole-4-carbox-amide-1-beta-D-ribofuranoside (AICAR) reduces lipoteichoic acid-induced lung inflammation. The Journal of biological chemistry. 2013; 288:7047-7052.
101. Zhang Y, Storr SJ, Johnson K, Green AR, Rakha EA, Ellis IO, Morgan DA and Martin SG. Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy. Oncotarget. 2014; 5:12936-12949.
102. Tebbe C, Chhina J, Dar SA, Sarigiannis K, Giri S, Munkarah AR and Rattan R. Metformin limits the adipocyte tumor-promoting effect on ovarian cancer. Oncotarget. 2014; 5:4746-4764.
103. Morales DR and Morris AD. Metformin in Cancer Treatment and Prevention. Annual review of medicine. 2014.
104. Kasznicki J, Sliwinska A and Drzewoski J. Metformin in cancer prevention and therapy. Annals of translational medicine. 2014; 2:57.
105. Zhang ZJ, Zheng ZJ, Shi R, Su Q, Jiang Q and Kip KE. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. The Journal of clinical endocrinology and metabolism. 2012; 97:2347-2353.
106. Yang Y. Metformin for cancer prevention. Frontiers of medicine. 2011; 5:115-117.
107. Storozhuk Y, Hopmans SN, Sanli T, Barron C, Tsiani E, Cutz JC, Pond G, Wright J, Singh G and Tsakiridis T. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. British journal of cancer. 2013; 108:2021-2032.
108. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD and Dennis PA. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer prevention research. 2010; 3:1066-1076.
109. Saito T, Chiba T, Yuki K, Zen Y, Oshima M, Koide S, Motoyama T, Ogasawara S, Suzuki E, Ooka Y, Tawada A, Tada M, Kanai F, Takiguchi Y, Iwama A and Yokosuka O. Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. PloS one. 2013; 8:e70010.
110. Hosono K, Endo H, Takahashi H, Sugiyama M, Uchiyama T, Suzuki K, Nozaki Y, Yoneda K, Fujita K, Yoneda M, Inamori M, Tomatsu A, Chihara T, Shimpo K, Nakagama H and Nakajima A. Metformin suppresses azoxymethaneinduced colorectal aberrant crypt foci by activating AMPactivated protein kinase. Molecular carcinogenesis. 2010; 49:662-671.
111. Ahren B, Mathieu C, Bader G, Schweizer A and Foley JE. Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia. 2014.
112. Mantovani A, Allavena P, Sica A and Balkwill F. Cancerrelated inflammation. Nature. 2008; 454:436-444.
113. Din FV, Theodoratou E, Farrington SM, Tenesa A, Barnetson RA, Cetnarskyj R, Stark L, Porteous ME, Campbell H and Dunlop MG. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut. 2010; 59:1670-1679.
114. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP and Meade TW. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year followup of five randomised trials. Lancet. 2010; 376:1741-1750.
115. Grossman HB. Selective COX-2 inhibitors as chemopreventive and therapeutic agents. Drugs of today. 2003; 39:203-212.
116. Din FV, Valanciute A, Houde VP, Zibrova D, Green KA, Sakamoto K, Alessi DR and Dunlop MG. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology. 2012; 142:1504-1515 e1503.
117. Russe OQ, Moser CV, Kynast KL, King TS, Stephan H, Geisslinger G and Niederberger E. Activation of the AMPactivated protein kinase reduces inflammatory nociception. The journal of pain: official journal of the American Pain Society. 2013; 14:1330-1340.
118. Mann J. Natural products in cancer chemotherapy: past, present and future. Nature reviews Cancer. 2002; 2:143-148.
119. Lee DH, Lee TH, Jung CH and Kim YH. Wogonin induces apoptosis by activating the AMPK and p53 signaling pathways in human glioblastoma cells. Cellular signalling. 2012; 24:2216-2225.
120. Yun SM, Jung JH, Jeong SJ, Sohn EJ, Kim B and Kim SH. Tanshinone IIA induces autophagic cell death via activation of AMPK and ERK and inhibition of mTOR and p70 S6K in KBM-5 leukemia cells. Phytotherapy research: PTR. 2014; 28:458-464.
121. Russo GL. Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochemical pharmacology. 2007; 74:533-544.
122. Lee YK, Park SY, Kim YM, Lee WS and Park OJ. AMP kinase/cyclooxygenase-2 pathway regulates proliferation and apoptosis of cancer cells treated with quercetin. Experimental & molecular medicine. 2009; 41:201-207.
123. Park IJ, Yang WK, Nam SH, Hong J, Yang KR, Kim J, Kim SS, Choe W, Kang I and Ha J. Cryptotanshinone induces G1 cell cycle arrest and autophagic cell death by activating the AMP-activated protein kinase signal pathway in HepG2 hepatoma. Apoptosis: an international journal on programmed cell death. 2014; 19:615-628.
124. Puissant A, Robert G, Fenouille N, Luciano F, Cassuto JP, Raynaud S and Auberger P. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer research. 2010; 70:1042-1052.
125. Park JB, Lee MS, Cha EY, Lee JS, Sul JY, Song IS and Kim JY. Magnolol-induced apoptosis in HCT-116 colon cancer cells is associated with the AMP-activated protein kinase signaling pathway. Biological & pharmaceutical bulletin. 2012; 35:1614-1620.
126. Hwang JT, Ha J, Park IJ, Lee SK, Baik HW, Kim YM and Park OJ. Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway. Cancer letters. 2007; 247:115-121.
127. Kang MR, Park SK, Lee CW, Cho IJ, Jo YN, Yang JW, Kim JA, Yun J, Lee KH, Kwon HJ, Kim BW, Lee K, Kang JS and Kim HM. Widdrol induces apoptosis via activation of AMP-activated protein kinase in colon cancer cells. Oncology reports. 2012; 27:1407-1412.
128. Zhang Y, Xu S, Lin J, Yao G, Han Z, Liang B, Zou Z, Chen Z, Song Q, Dai Y, Gao T, Liu A and Bai X. mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo. Breast cancer research and treatment. 2012; 136:379-388.
129. Shieh JM, Chen YC, Lin YC, Lin JN, Chen WC, Chen YY, Ho CT and Way TD. Demethoxycurcumin inhibits energy metabolic and oncogenic signaling pathways through AMPK activation in triple-negative breast cancer cells. Journal of agricultural and food chemistry. 2013; 61:6366-6375.
130. Pan W, Yang H, Cao C, Song X, Wallin B, Kivlin R, Lu S, Hu G, Di W and Wan Y. AMPK mediates curcumininduced cell death in CaOV3 ovarian cancer cells. Oncology reports. 2008; 20:1553-1559.
131. Song G, Mao YB, Cai QF, Yao LM, Ouyang GL and Bao SD. Curcumin induces human HT-29 colon adenocarcinoma cell apoptosis by activating p53 and regulating apoptosisrelated protein expression. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas/Sociedade Brasileira de Biofisica [et al]. 2005; 38:1791-1798.
132. Khanal P, Oh WK, Yun HJ, Namgoong GM, Ahn SG, Kwon SM, Choi HK and Choi HS. p-HPEA-EDA, a phenolic compound of virgin olive oil, activates AMP-activated protein kinase to inhibit carcinogenesis. Carcinogenesis. 2011; 32:545-553.
133. Chiang PC, Lin SC, Pan SL, Kuo CH, Tsai IL, Kuo MT, Wen WC, Chen P and Guh JH. Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: a crucial role of AMPK and mTOR pathways. Biochemical pharmacology. 2010; 79:162-171.
134. Nagalingam A, Arbiser JL, Bonner MY, Saxena NK and Sharma D. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast cancer research: BCR. 2012; 14:R35.
135. Li W, Hua B, Saud SM, Lin H, Hou W, Matter MS, Jia L, Colburn NH and Young MR. Berberine regulates AMPactivated protein kinase signaling pathways and inhibits colon tumorigenesis in mice. Molecular carcinogenesis. 2014.
136. Santidrian AF, Gonzalez-Girones DM, Iglesias-Serret D, Coll-Mulet L, Cosialls AM, de Frias M, Campas C, Gonzalez-Barca E, Alonso E, Labi V, Viollet B, Benito A, Pons G, Villunger A and Gil J. AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells. Blood. 2010; 116:3023-3032.
137. Sengupta TK, Leclerc GM, Hsieh-Kinser TT, Leclerc GJ, Singh I and Barredo JC. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Molecular cancer. 2007; 6:46.
138. Su RY, Chao Y, Chen TY, Huang DY and Lin WW. 5-Aminoimidazole-4-carboxamide riboside sensitizes TRAIL-and TNF{alpha}-induced cytotoxicity in colon cancer cells through AMP-activated protein kinase signaling. Molecular cancer therapeutics. 2007; 6:1562-1571.
139. Wang S, Penchala S, Prabhu S, Wang J and Huang Y. Molecular basis of traditional Chinese medicine in cancer chemoprevention. Current drug discovery technologies. 2010; 7:67-75.
140. Yin J, Zhang H and Ye J. Traditional chinese medicine in treatment of metabolic syndrome. Endocrine, metabolic & immune disorders drug targets. 2008; 8:99-111.
141. Huang Z, Xu X, Lu F, Wang N, Chen G, Zhao Y, Zou X, Wang K, Dong H and Xu L. Jiao tai wan attenuates hepatic lipid accumulation in type 2 diabetes mellitus. Evidencebased complementary and alternative medicine: eCAM. 2013; 2013:567045.
142. Yin J, Luo Y, Deng H, Qin S, Tang W, Zeng L and Zhou B. Hugan Qingzhi medication ameliorates hepatic steatosis by activating AMPK and PPARalpha pathways in L02 cells and HepG2 cells. Journal of ethnopharmacology. 2014; 154:229-239.
143. Rios M, Foretz M, Viollet B, Prieto A, Fraga M, Costoya JA and Senaris R. AMPK activation by oncogenesis is required to maintain cancer cell proliferation in astrocytic tumors. Cancer research. 2013; 73:2628-2638.
144. Martin MJ, Hayward R, Viros A and Marais R. Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer discovery. 2012; 2:344-355.
145. Rokhlin OW, Taghiyev AF, Bayer KU, Bumcrot D, Koteliansk VE, Glover RA and Cohen MB. Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival. Cancer biology & therapy. 2007; 6:732-742.